Widely used:Recently Viewed
Clear All
$477 Mln
--
0.81
--
0
-24.53 %
--
--
--
-2357578
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
| -55.43 | -44.43 | -66.83 | -13.67 | -30.06 | -- | -- |
|
BSE Sensex*
| 13.21 | -1.34 | 1.57 | 23.38 | 10.08 | 16.44 | 11.99 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
| -8.78 | 1.23 | -47.07 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$476.56 Mln
$20.22 Mln
$0.00 Mln
$541.95 Mln
$13.66 Mln
Low
$8.53 - 36.25
51,969,600
NASDAQ: FDMT
EmeryVille, CA
https://www.4dmoleculartherapeutics.com
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine... product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California. Address: 5858 Horton Street, EmeryVille, CA, United States, 94608 Read more
The total asset value of 4D Molecular Therapeutics Inc (FDMT) stood at $ 640 Mln as on 30-Jun-24
The share price of 4D Molecular Therapeutics Inc (FDMT) is $9.03 (NASDAQ) as of 14-Oct-2024 16:00 EDT. 4D Molecular Therapeutics Inc (FDMT) has given a return of -30.06% in the last 3 years.
4D Molecular Therapeutics Inc (FDMT) has a market capitalisation of $ 477 Mln as on 14-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of 4D Molecular Therapeutics Inc (FDMT) is 0.81 times as on 14-Oct-2024, a 74% discount to its peers’ median range of 3.10 times.
Since, TTM earnings of 4D Molecular Therapeutics Inc (FDMT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 4D Molecular Therapeutics Inc (FDMT) and enter the required number of quantities and click on buy to purchase the shares of 4D Molecular Therapeutics Inc (FDMT).
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California. Address: 5858 Horton Street, EmeryVille, CA, United States, 94608
The CEO & director of Dr. John F. Milligan Ph.D.. is 4D Molecular Therapeutics Inc (FDMT), and CFO & Sr. VP is Dr. John F. Milligan Ph.D..
There is no promoter pledging in 4D Molecular Therapeutics Inc (FDMT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,048
|
|
|
988
|
|
|
965
|
|
|
900
|
| 4D Molecular Therapeutics Inc (FDMT) | Ratios |
|---|---|
|
Return on equity(%)
|
-24.53
|
|
Operating margin(%)
|
-649.02
|
|
Net Margin(%)
|
-543.54
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of 4D Molecular Therapeutics Inc (FDMT) was $0 Mln.
$-0.14
